Introduction
Porokeratosis is a clonal disorder of keratinocytes characterized by annular atrophic plaques surrounded by ridge-like borders that expand centrifugally, with the histological feature of cornoid lamella, a column of parakeratotic cells. Five clinical variants of porokeratosis have been described: Mibelli disease, disseminated superficial (actinic), porokeratosis palmaris et plantaris disseminata, linear, and punctate porokeratosis. 1 Porokeratosis lesions result from the peripheral expansion of an abnormal mutant clone of epidermal keratinocytes, which may be triggered by light, trauma, infection, or immunosuppression. 2 In immunosuppressed patients, it is usually the disseminated superficial (actinic) porokeratosis (DSP) variant that is seen, typically appearing on extremities symmetrically and less often the trunk. [3] [4] Immunosuppression-induced DSP has been reported in the literature in the context of 
Case Report
A 39-year-old Caucasian woman presented with multiple scattered, erythematous, blanchable, well-defined papules and plaques with atrophic centers. The lesions appeared suddenly on her lower legs, forearms, and upper chest. Initially asymptomatic, they soon became pruritic. She had signs of actinic damage including solar lentigines on her face, chest, back, and upper extremities; however, she denied recent sun exposure. She also denied any personal or family history of previous rashes. The patient had a past medical history of well-controlled asthma and treated histoplasmosis ten years prior. She gave a history of vomiting and diarrhea of one day's duration a month prior and a twenty-four pound weight loss since this episode due to lack of appetite. Furthermore, she had a non-productive, persistent cough with periodic shortness of breath and wheezing that was not ameliorated by a week-long course of levofloxacin.
She was treated with a prednisone taper two weeks prior to presentation for suspected asthma flair secondary to viral infection, after extensive work-up and rule out of active histoplasmosis, tuberculosis, or underlying pulmonary malignancy. Her taper started at 60 mg daily for one week, reduced by 20 mg every three days thereafter. The rash appeared three days following cessation of oral steroids (two days after completing levofloxacin). Eruptive Disseminated Porokeratosis
In concordance with EDP as a paraneoplastic syndrome 4 , as pulmonary malignancy was ruled out, the trigger for EDP in our patient was likely due to immunosuppression secondary to systemic corticosteroid therapy. Also included in the differential is EDP secondary to an idiosyncratic drug reaction to the antibiotic she had recently taken, akin to a recent report citing a similar presentation suggestive of perioperative flucloxacillin and/or gentamicin causing EDP in a 63-year-old man. 9 However, the disparity in lesion resolution time and classes of antibiotics used between the cases makes this less likely. In fact, there are reports of other drugs causing EDP such as anti-TNF therapy 6 and sumarin 8 that, while not directly applicable in our patient, should be considered in future cases. As our patient's asthma attack was questionably viral in etiology, one could argue that this infection was the nidus for the EDP episode; however, as testing for viral serology is not clinically indicated in such a setting, one could only speculate this potentially contributing. Since our patient had a history of diarrhea, conceivably she may have always had DSP and developed enterovirus-associated eruptive pseudoangiomatosis (EP) in these areas that made the lesions manifest; however, we consider this much less likely based off the history, clinical and histopathological findings, and probability of having a rare disease like EP in conjunction with DSP. After thorough literature review, we can affirm our case is indeed the second case of EDP most likely related to corticosteroid-induced immunosuppression. Skin lesions of EDP in our patient have gradually improved after discontinuing oral steroid therapy with no other directly implemented therapy. In summary, we describe a case of EDP following systemic corticosteroid therapy immunosuppression, which is only the second case described in the literature.
Learning Points
• Eruptive disseminated porokeratosis (EDP) is a recently described and characterized form of porokeratosis involving the sudden onset of erythematous pruritic papules and plaques.
• A high percentage of EDP cases occurred in the context of internal malignancy and immunosuppression.
• Corticosteroid use can induce EDP.
• EDP should alert the physician to strongly consider underlying immunosuppression and malignancies.
• EDP may now be added as the sixth variant of the Porokeratoses.
Learning objective: To demonstrate knowledge of eruptive disseminated porokeratosis and risk factors surrounding it. 
